How Cannabis Stock Analysts Have Revised Their Outlooks

You’re reading a copy of this week’s edition of the New Cannabis Ventures weekly newsletter, which we have been publishing since October 2015. The newsletter includes unique insight to help our readers stay ahead of the curve as well as links to the week’s most important news.

Subscribe to receive our free weekly newsletter in your inbox each Sunday morning.


Over the next month, the leading American cannabis companies will be reporting their 4th quarter financial results, beginning with Green Thumb Industries on March 1st and Curaleaf on March 3rd. Several companies will be introducing guidance for 2022, including Curaleaf, Trulieve and Verano among the largest five. GTI has never provided guidance, and Cresco typically hasn’t done so. Ayr Wellness and Jushi have already provided their outlooks, and we anticipate that Ascend Wellness and Columbia Care could do so as well. We expect TerrAscend will again provide a full-year outlook, but perhaps it will wait until it closes the GAGE Growth acquisition to do so.

As we have discussed previously, the timing of New Jersey commencing adult-use sales is a major factor in terms of potential revenue in 2022 for many of these companies, so we could see guidance with asterisks from some operators. Further clouding the crystal balls has been a recent trend of sluggish cannabis sales across many states. For these reasons, analysts have already been revising their expectations lower. In the table below, we share the current 2022 revenue and growth projection, according to Sentieo, and also show how it has changed since the end of November for each of the ten largest companies by market cap:

The average projected growth is quite robust at 61%, some of which is from acquisitions, but eight of the ten companies have seen declines since the end of November. The average decline of 3% is modest. We note that the analyst revenue consensus for Ayr Wellness is below the company’s guidance of $800 million provided in November, while the estimate for Jushi is consistent with the range of $375-425 million that the company reaffirmed in November.

Given the factors discussed above, we view the current consensus numbers as likely a bit too high. With that said, we believe that investors are well aware of the recent sluggishness in cannabis sales and the delay in New Jersey. From our perspective, the valuations are low enough at this point to accommodate somewhat lower outlooks, especially from companies leveraged to New Jersey.

After 13 extremely successful editions in Toronto, Chicago, Detroit, New York and Miami, the Benzinga Cannabis Capital Conference is going bigger than ever. Join us at the Fontainebleau Hotel in Miami Beach on April 20th and 21st.

For the first time ever, browse the expo floor and discover to the brands that are shaping the cannabis industry. In addition, attendees will enjoy private meeting areas, comfortable seating and premium food options. Join live in Florida or attend from home. There’s no better place to connect with the people driving the global cannabis industry forward.

Subscribers to the New Cannabis Ventures newsletter can use the code “NCVVIP” for 30% off your ticket

New Cannabis Ventures publishes curated articles as well as exclusive news. Here is some of the most interesting business content from this week:

To get real-time updates download our free mobile app for Android or Apple devices, like our Facebook page, or follow Alan on Twitter. Share and discover industry news with like-minded people on the largest cannabis investor and entrepreneur group on LinkedIn.

Get ahead of the crowd! If you are a cannabis investor and find value in our Sunday newsletters, subscribe to 420 Investor, Alan’s comprehensive stock due diligence platform since 2013. Gain immediate access to real-time and in-depth information and market intelligence about the publicly traded cannabis sector, including daily videos, weekly chats, model portfolios, a community forum and much more.

Use the suite of professionally managed NCV Cannabis Stock Indices to monitor the performance of publicly-traded cannabis companies within the day or over longer time-frames. In addition to the comprehensive Global Cannabis Stock Index, we offer a family of indices to track Canadian licensed producers as well as the American Cannabis Operator Index and the Ancillary Cannabis Index.

View the Public Cannabis Company Revenue & Income Tracker, which ranks the top revenue producing cannabis stocks.

Stay on top of some of the most important communications from public companies by viewing upcoming cannabis investor earnings conference calls.

Discover upcoming new listings with the curated Cannabis Stock IPOs and New Issues Tracker.


Alan & Joel

Exclusive article by Alan Brochstein, CFA
Alan Brochstein, CFA
Based in Houston, Alan leverages his experience as founder of online community 420 Investor, the first and still largest due diligence platform focused on the publicly-traded stocks in the cannabis industry. With his extensive network in the cannabis community, Alan continues to find new ways to connect the industry and facilitate its sustainable growth. At New Cannabis Ventures, he is responsible for content development and strategic alliances. Before shifting his focus to the cannabis industry in early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent research analyst following over two decades in research and portfolio management. A prolific writer, with over 650 articles published since 2007 at Seeking Alpha, where he has 70,000 followers, Alan is a frequent speaker at industry conferences and a frequent source to the media, including the NY Times, the Wall Street Journal, Fox Business, and Bloomberg TV. Contact Alan: Twitter | Facebook | LinkedIn | Email

Get Our Sunday Newsletter